A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
← catalyst calendarNCT07612267 · readout ≤ 773 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
14estimated
Sites
22
Countries
Canada, Denmark, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lactation
- Inflammatory Bowel Disease
Intervention
- Drug: Mirikizumab — also filed as LY3074828
Primary outcome
what the primary-completion date above is the date OFConcentration of Mirikizumab in Breast Milk
measured Predose up to 28 Days
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed